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IMPACT OF NATIONAL HEALTH INSURANCE ON
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IN TAIWAN: REVIEW OF 74 PATIENTS
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The 2-year survival rate for high-grade osteosarcoma was 46.9% before the introduction of National Health
Insurance (NHI) in Taiwan on March 1, 1995, but increased to 73.8% after the implementation of NHI.
The 5-year survival rate also increased, from 37.5% to 63.6%. Between May 1990 and May 2001, 74 patients
with high-grade osteosarcoma were treated at our hospital. Median age was 17 years (range, 7–63 years).
Inadequate surgical margins, poor histologic response to chemotherapy, advanced stage of disease, and
incomplete treatment were strongly associated with poor prognosis. Before NHI, 10 patients had incomplete
treatment, mainly because of unaffordable medical fees. After NHI, only three patients had incomplete
treatment, due to personal reasons. Patient survival improved dramatically with advances in multiagent
chemotherapy, but it was the NHI that enabled patients to complete expensive treatment courses, including
preoperative neoadjuvant chemotherapy, limb-salvage surgery, and postoperative adjuvant chemotherapy.
The NHI also improved the accessibility of medical care, with more patients presenting in the early stages
of disease and, as a result, it not only improved survival rate but also increased the number of patients
undergoing limb-salvage surgery. We concluded that the NHI significantly improved the survival rate
for patients with osteosarcoma in Taiwan.
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Osteosarcoma is the most common primary malignancy of
bone, with an aggressive local pattern of growth and high
metastatic potential [1]. Since the advent of multiagent
adjuvant and neoadjuvant chemotherapy, patient survival
has improved dramatically [2–4]. In our study, poor response
to chemotherapy, inadequate surgical margin, advanced
stage of disease, and incomplete treatment were all related
to poor prognosis.
The government of Taiwan introduced the National
Health Insurance (NHI), to cover all citizens, on March 1,
1995. Before the implementation of NHI, complete treat-
ment for osteosarcoma was unaffordable for most patients.
The average cost of complete neoadjuvant chemother-
apy was NT$300,000 (US$8,571), for complete adjuvant
chemotherapy was NT$700,000 (US$20,000), and for limb-
salvage surgery was NT$300,000 (US$8,571). Amputations
were more popular because they incurred less medical
expense. The high cost of medical treatment might have
hindered the accessibility of appropriate management for
osteosarcoma in the early stages of the disease and, as a
result, patients always presented to the hospital in the
advanced stages of disease. After the implementation of
NHI, these barriers were removed. Under the NHI system,
all treatments are free of charge for patients with osteosar-
coma. This study was conducted to analyze the influence
of NHI on the survival rate for osteosarcoma.
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MATERIALS AND METHODS
Between May 1990 and May 2001, 74 patients with high-
grade osteosarcoma of the extremities were treated at our
hospital. The median age was 17 years (range, 7–63 years).
The 44 males and 30 females were followed for 2 to 13
years after osteosarcoma treatment; 32 patients were treated
before the implementation of NHI and 42 after the imple-
mentation of NHI.
Lesions were located in the proximal humerus in four
patients, in the proximal femur in five, in the distal femur in
40, in the proximal tibia in 17, in the distal tibia in two, in the
proximal fibula in four, and in the distal fibula in two. The
Enneking staging system was used throughout the study
[5]. Nine patients presented with stage IIA lesions, 42 with
stage IIB lesions, six with stage IIIA lesions, and 17 with
stage IIIB lesions.
Treatment included limb-salvage surgery, amputation,
and incomplete treatment (Table 1). Rotationplasties were
regarded as amputations [6,7]. Incomplete treatment was
defined as biopsy without further management, incomplete
neoadjuvant chemotherapy after biopsy, or refusal of sur-
gery after completing neoadjuvant chemotherapy. Fifty-
one patients completed neoadjuvant and adjuvant chemo-
therapy, and their histologic response to chemotherapy
was classified as “good” (≥ 90% tumor necrosis) or “poor”
(< 90% tumor necrosis) [8]. Before 1995, methotrexate was
used for preoperative and postoperative chemotherapy,
but it was changed to doxorubicin and cisplatin postopera-
tively because of poor histologic response with methotrex-
ate. After 1995, we used high-dose methotrexate, cisplatin
or carboplatin, and doxorubicin for neoadjuvant chemo-
therapy, and we added ifosfamide postoperatively for
patients with poor histologic response. The 2- and 5-year
overall survival rates were calculated without considering
the influence of NHI. The 2- and 5-year survival rates before
and after the implementation of NHI were analyzed using
the Kaplan-Meier method.
RESULTS
Of the 51 patients who received neoadjuvant chemother-
apy, 31 had good histologic response (60.8%) and 20 had
poor histologic response (39.2%). The 2-year survival rates
for patients with good and poor histologic response to
chemotherapy were 100% and 40% (8/20), respectively.
Nine patients had inadequate surgical margins. Six pa-
tients developed local recurrence and their 2-year survival
rate was 16.7% (1/6).
Before the implementation of NHI, four patients pre-
sented with stage IIIA and 11 with stage IIIB lesions. Af-
ter NHI implementation, there were two stage IIIA and
six stage IIIB lesions. The overall 2-year survival rate for
stage IIA disease was 100%, for stage IIB was 81%, for stage
IIIA was 50%, and for stage IIIB was 0%.
Ten patients had incomplete treatment before the im-
plementation of NHI, which decreased to three patients
after NHI implementation. For patients with incomplete
treatment, the 2-year survival rate was 15.4% (2/13).
The 2- and 5-year overall survival rates without con-
sidering the influence of NHI were 62.2% (46/74) and 48.1%
(26/54), respectively. The 2-year survival rates before and
after implementation of NHI were 46.9% (15/32) and 73.8%
(31/42), respectively (Figure 1). The 5-year survival rates
before and after implementation of NHI were 37.5% (12/32)
and 63.6% (14/22), respectively (Figure 2).
DISCUSSION
This retrospective study analyzed the influence of NHI on
the survival rate of patients with osteosarcoma. The 2- and
5-year overall survival rates were 62.2% and 48.1%, re-
spectively. These are lower than the rates in other reports
[6,9–11]. We identified several factors that could influence
the survival rate of our patients. Patients with inadequate
Table 1. Type of treatment for patients with osteosarcoma
at Kaohsiung Medical University Hospital
Limb-salvage surgery (n = 33)
Custom-made knee prosthesis 21
Custom-made hip prosthesis 3
Shoulder prosthesis 1
Wide excision with allograft 6
Wide excision with autoclave autograft 1
Wide excision with limb lengthening 1
Amputation (n = 28)
Below-the-knee amputation 1
Above-the-knee amputation 10
Hip disarticulation 14
Segmental amputation 1
Rotationplasty 2
Incomplete treatment (n = 13)
Biopsy 5
Biopsy and incomplete neoadjuvant chemotherapy 6
Biopsy and complete neoadjuvant chemotherapy 2
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surgical margins had a higher rate of local recurrence and
their 2-year survival rate was very low. Patients with poor
histologic response to chemotherapy also had lower survi-
val rates compared to those with good histologic response.
Bacci et al suggested immediate amputation for patients
with inadequate surgical margins and poor histologic re-
sponse to preoperative chemotherapy [6,12]. Advanced
stage of disease and incomplete treatment were strongly
associated with poor prognosis.
On March 1, 1995, the government of Taiwan introduced
NHI to cover all citizens. This NHI program was proposed
to ensure that patients have access to health care at a rea-
sonable cost [13]. We noted a significant difference in sur-
vival rates before and after the implementation of NHI. Be-
fore NHI implementation, the 2- and 5-year survival rates
were 46.9% and 37.5%, respectively. After implementa-
tion, these rates increased to 73.8% and 63.6%, respectively.
Under the NHI system, all treatments for osteosarcoma are
free of charge. NHI makes complete treatment accessible to
patients. Before NHI implementation, only a few patients
could afford to pay the expensive medical fees. More ampu-
tations were performed before NHI implementation be-
cause of the lower medical expenses and because patients
presented with advanced disease that was untreatable with
limb-salvage surgery. Use of the limb-salvage procedure
increased significantly after NHI implementation (Table 2).
We attributed this to coverage of medical expenses by the
NHI, more patients presenting in the early stages of disease,
improvement in the efficacy of chemotherapy, improved
operative techniques, and advances in prosthetic design.
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Figure 2. Kaplan-Meier analysis of 5-year survival of patients with
osteosarcoma treated before and after the implementation of National
Health Insurance.
Figure 1. Kaplan-Meier analysis of 2-year survival of patients with
osteosarcoma treated before and after the implementation of National
Health Insurance.
Table 2. Number of patients who received incomplete treatment, amputation and limb-salvage surgery between 1990 and 2001
Incomplete treatment Amputation Limb-salvage surgery
1990 2 4 0
1991 3 2 1
1992 1 4 1
1993 1 3 0
1994 3 4 1
1995 1 3 2
1996 1 3 4
1997 0 1 5
1998 0 2 6
1999 1 1 5
2000 0 1 3
2001 0 0 5
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Limb-salvage surgery became the main surgical procedure
instead of amputation for treatment of osteosarcoma of the
extremity in our hospital as well as many other medical
centers [4,14,15].
Advances in adjuvant and neoadjuvant chemotherapy
improved the survival rate dramatically for patients with
osteosarcoma [2–4]. Chemotherapy remains the chief factor
in curing patients with osteosarcoma and every attempt
should be made to increase its efficacy [7]. However, it was
the NHI that enabled patients to complete the expensive
treatment courses. The implementation of NHI improved
the accessibility of medical care among the general popula-
tion, with more patients presenting at the early stage of
disease. Therefore, a better survival rate was expected after
NHI implementation. Without the NHI, despite the advances
in chemotherapy and surgical technique, most patients
with osteosarcoma would not receive adequate treatment,
due to socioeconomic factors. We therefore conclude that
the NHI had a great impact and improved the survival rate
of patients with osteosarcoma in Taiwan.
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